
Adamis Pharmaceuticals Corporation ADMP
Quarterly report 2023-Q3
added 11-14-2023
Adamis Pharmaceuticals Corporation Operating Expenses 2011-2026 | ADMP
Annual Operating Expenses Adamis Pharmaceuticals Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 38.9 M | 35.7 M | 44.7 M | 30.3 M | 26.8 M | 13.9 M | 4.4 M | 3.22 M | 4.82 M | 6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 44.7 M | 3.22 M | 20.9 M |
Operating Expenses of other stocks in the Drug manufacturers industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aerie Pharmaceuticals
AERI
|
213 M | - | - | $ 754 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
40.3 M | - | 7.5 % | $ 6.35 M | ||
|
Catalent
CTLT
|
512 M | - | - | $ 11.5 B | ||
|
DURECT Corporation
DRRX
|
44.6 M | - | - | $ 50.1 M | ||
|
Endo International plc
ENDP
|
763 M | - | - | $ 28.9 M | ||
|
Agile Therapeutics
AGRX
|
30.5 M | - | 10.11 % | $ 58.2 M | ||
|
Canopy Growth Corporation
CGC
|
197 M | $ 1.1 | 2.84 % | $ 118 M | ||
|
Evoke Pharma
EVOK
|
12.6 M | - | - | $ 36.6 M | ||
|
Alimera Sciences
ALIM
|
71.8 M | - | - | $ 142 M | ||
|
Cronos Group
CRON
|
154 M | $ 2.64 | 1.35 % | $ 1.38 B | ||
|
Evolus
EOLS
|
107 M | $ 5.68 | 37.53 % | $ 366 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
196 M | - | - | $ 2.06 B | ||
|
Jupiter Wellness
JUPW
|
39.6 M | - | - | $ 33.6 M | ||
|
China Pharma Holdings
CPHI
|
2.6 M | $ 0.59 | 6.08 % | $ 10.3 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
35.2 M | $ 3.81 | -16.81 % | $ 53.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
213 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
106 M | - | 2.45 % | $ 38.1 M | ||
|
Harrow Health
HROW
|
174 M | $ 40.02 | 3.65 % | $ 1.47 B | ||
|
Neoleukin Therapeutics
NLTX
|
55.6 M | - | - | $ 193 M | ||
|
Aurora Cannabis
ACB
|
183 M | $ 3.65 | 4.89 % | $ 86.3 M | ||
|
Athenex
ATNX
|
96.7 M | - | -23.39 % | $ 1.76 M | ||
|
Emergent BioSolutions
EBS
|
558 M | $ 8.95 | 0.39 % | $ 458 M | ||
|
ProPhase Labs
PRPH
|
47.1 M | - | - | $ 5.07 M | ||
|
Assertio Holdings
ASRT
|
133 M | $ 12.19 | 2.48 % | $ 866 M | ||
|
Radius Health
RDUS
|
304 M | - | - | $ 1.42 B | ||
|
Bausch Health Companies
BHC
|
4.96 B | $ 5.67 | -0.87 % | $ 2.07 B | ||
|
Lannett Company
LCI
|
209 M | - | 1.15 % | $ 7.11 M | ||
|
Eagle Pharmaceuticals
EGRX
|
113 M | - | -39.89 % | $ 27.7 M | ||
|
Organogenesis Holdings
ORGO
|
368 M | $ 2.87 | 0.01 % | $ 378 M | ||
|
OrganiGram Holdings
OGI
|
41.4 M | $ 1.4 | 2.19 % | $ 402 M | ||
|
Rockwell Medical
RMTI
|
31.1 M | $ 0.91 | 1.03 % | $ 21.2 M | ||
|
Perrigo Company plc
PRGO
|
2.62 B | $ 11.71 | 2.81 % | $ 1.62 B | ||
|
Sundial Growers
SNDL
|
102 K | $ 1.55 | 1.21 % | $ 3.37 M | ||
|
TherapeuticsMD
TXMD
|
9.82 M | $ 2.25 | 1.35 % | $ 23.5 M | ||
|
Veru
VERU
|
44 M | $ 2.53 | 0.4 % | $ 341 M | ||
|
Viatris
VTRS
|
5.67 B | $ 14.74 | -1.04 % | $ 17.7 B | ||
|
Pacira BioSciences
PCRX
|
279 M | $ 22.92 | 3.69 % | $ 1.06 B | ||
|
PetIQ
PETQ
|
138 M | - | 1.64 % | $ 400 M | ||
|
OptiNose
OPTN
|
129 M | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
44.2 M | - | -27.8 % | $ 2.56 M | ||
|
Recro Pharma
REPH
|
22.5 M | - | -4.76 % | $ 65.3 M | ||
|
Relmada Therapeutics
RLMD
|
104 M | $ 4.79 | 2.57 % | $ 144 M | ||
|
cbdMD
YCBD
|
28.9 M | $ 0.75 | -2.76 % | $ 3.23 M | ||
|
SCYNEXIS
SCYX
|
67.5 M | $ 0.76 | 1.22 % | $ 36.4 M | ||
|
Solid Biosciences
SLDB
|
130 M | $ 6.14 | 3.02 % | $ 251 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
9.18 M | $ 2.74 | -0.36 % | $ 3.4 M | ||
|
Tricida
TCDA
|
153 M | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
1.52 B | $ 7.33 | -0.48 % | $ 4.53 B | ||
|
Zynerba Pharmaceuticals
ZYNE
|
35.3 M | - | - | $ 55.5 M |